INDICATIONS

PAVBLU® (aflibercept-ayyh) is indicated for the treatment of Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular
Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR).

PAVBLU® is not indicated for Retinopathy of Prematurity, for which Regeneron has marketing exclusivity.

PAVBLU® (aflibercept-ayyh) is indicated for the treatment of Neovascular (Wet) Age-Related Macular Degeneration...Read more

PAVBLU® (aflibercept-ayyh) is indicated for the treatment of Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular
Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR)...Read more

Indications Prescribing Information AmgenSupportPlus.com AmgenBiosimilars.com

Understanding your treatment with PAVBLU®

Understanding your eye condition

PAVBLU® is a Food and Drug Administration (FDA)-approved prescription medication used to
treat the following eye conditions:1,*
  • Wet age-related macular degeneration, known as “wet AMD”
  • Diabetic macular edema (DME)
  • Diabetic retinopathy (DR)
  • Macular edema following retinal vein occlusion (RVO)

*PAVBLU® is not indicated for Retinopathy of Prematurity, for which Regeneron has marketing exclusivity.1,2

Wet AMD

Wet AMD is an age-related eye disease in which abnormal blood vessels grow under or into the
macula at the back of the eye. These may leak and damage the macula, a part of the retina
responsible for central vision.3,4

Diabetic macular edema (DME) and diabetic retinopathy (DR)

DR occurs when diabetes damages blood vessels in the retina. DME occurs when those damaged
vessels leak fluid into the macula, causing swelling and vision problems.5-7

Macular edema following retinal vein occlusion, or RVO

RVO occurs when a retinal vein becomes blocked, which can cause blood and fluid to leak into
the retina and damage vision.8

All of these conditions cause leaking fluid
in the back of the eye and can damage
the retina.1,9

VEGF = vascular endothelial growth factor.

Diagram illustrating retina damage caused by VEGF protein production
Symptoms of these conditions can include:9-11
Symptoms of Wet AMD, DME, DR, and RVO
  • « Straight lines begin to look wavy or crooked
  • « Blurry area near the center of your vision
  • « Blank spots, dark spots, or little squiggles in vision (floaters)
  • « Trouble seeing in low light
  • « Sudden blurring or loss of vision (over days to weeks)
Is there a treatment for these conditions?
PAVBLU® is an anti-VEGF treatment that can
help with these conditions. VEGF (vascular
endothelial growth factor) is a protein made
by our cells to form blood vessels. When it is
produced at high levels, it can cause the
overgrowth of blood vessels and cause them to
leak fluid. PAVBLU® helps to block that protein.1,9
Diagram illustrating how PAVBLU™ (aflibercept) can block VEGF
Diagram illustrating PAVBLU™ (aflibercept-ayyh) mechanism of action
About Your Diagnosis Patient About-Your-Diagnosis-Patient-mob
Amgen is a worldwide

leader in innovator biologics
and biosimilars

PAVBLU® is a biosimilar of the biologic medicine called EYLEA®

Both PAVBLU® and EYLEA® work with your body to help stop or slow the progression of certain
retinal conditions. PAVBLU® is proven to provide a similar treatment benefit to EYLEA®.1-3

As part of the FDA approval for PAVBLU®, a clinical study compared PAVBLU® with EYLEA® in 576
adults with wet AMD. The study looked at vision after 8 weeks, and the results supported that there
were no clinically meaningful differences between PAVBLU® and EYLEA®. The study also continued
to follow patients for the 52 weeks of the study, and included a single transition group with patients
who transitioned from EYLEA® to PAVBLU®.4

Symptoms of wet AMD

In wet AMD, high levels of VEGF in the eye cause blood vessels to
grow and leak fluid into the macula, the part of the eye that controls
sharp, detailed central vision.1,5

PAVBLU® binds to VEGF, which helps prevent it from causing

new blood vessels to form and leak fluid in the eye.1
PAVBLU® can help stop or slow the progression of symptoms of your retinal disease, helping you maintain your current level of vision.1,3

AMD = age-related macular degeneration; VEGF = vascular endothelial growth factor.

Transitioning from EYLEA® TO PAVBLU®

The dosing and administration of PAVBLU® is identical and provides a similar experience if you are
transitioning from EYLEA®—no need to restart your dosing schedule1,2

PAVBLU® is given by your doctor in the same way and frequency
as EYLEA® for a highly similar TREATMENT experience1,2

PAVBLU™ (aflibercept) is administered using the same injection method as EYLEA®SAME INJECTION METHOD
PAVBLU™ (aflibercept) dosing frequency is the same as EYLEA®SAME DOSING FREQUENCY
How PAVBLU™ WORKS Patient How-PAVBLU-WORKS-mob
At Amgen, we’re committed
to every patient, every time

AMGEN—A worldwide leader in innovator biologics and biosimilars

Amgen has been providing biologic medicines to patients for more than 40 years. It’s known
throughout the world as a leader in research, development, and manufacturing of complex
medicines.

40+

Years

AMGEN has been
a leader in Biologics1

~10M

Patients are treated

with an Amgen medication
each year2

Amgen biosimilars are developed, manufactured, and distributed with the same high standards as our innovator biologics
Amgen has a global network of scientistsGLOBAL NETWORK OF SCIENTISTS
Amgen has the same key manufacturing facilities in North America and EuropeGLOBAL MANUFACTURING FACILITIES
Amgen has a state-of-the-art distribution networkSTATE-OF-THE-ART DISTRIBUTION NETWORK
Why AMGEN Biosimilars Patient Why-AMGEN-Biosimilars-mob
At Amgen, we maintain
the same standards for
all our medicines

Support throughout your treatment journey

Amgen® SupportPlus sample co-pay cardAMGEN® SUPPORTPLUS CO-PAY PROGRAM

Eligible commercially insured patients enrolled in the Amgen®
SupportPlus Co-Pay Program may be able to lower their out-of-
pocket costs for PAVBLU®.

  • May pay as little as $0* per dose
  • May receive up to $1,000 annually toward
    in-office administration costs*
  • No income eligibility requirement
enroll today

*Eligibility criteria and program maximums apply. See AmgenSupportPlus.com/copay for full
Terms and Conditions. Massachusetts and Rhode Island residents not eligible for in-office
administration support.

Government Insurance

PAVBLU® is a medication that falls under Medicare Part B instead of the usual prescription drug coverage
(Part D).

If you have government insurance, like Medicare, Amgen SupportPlus can provide information about resources that
may be able to lower your out-of-pocket costs.†

†Eligibility for resources provided by independent nonprofit patient assistance programs is based on the nonprofit's criteria. Amgen has no control over these programs and provides information as a courtesy only.

UNINSURED

If you are uninsured, Amgen SupportPlus may be able to provide information about third-party resources, or call
(866) 264-2778 Monday to Friday 8:30 am to 8:00 pm ET.

Amgen® SupportPlus provides financial support options by insurance type on their website.

DOWNLOAD FINANCIAL SUPPORT RESOURCES

Amgen® SupportPlus Co-Pay Program

Access a patient brochure
describing enrollment and claims
submission in the Amgen®
SupportPlus co-pay program

Understanding Medicare Options

Learn about and explore Medicare
options using this patient-friendly
brochure
Amgen® SupportPlus logo
Amgen® SupportPlus is here to help from the moment you're prescribed PAVBLU®. Visit AmgenSupportPlus.com or call Amgen® SupportPlus at (866) 264-2778. Monday to Friday 8:30 AM - 8:00 PM ET
My PAVBLU™ Guide
My PAVBLU™ Guide

My PAVBLU™ Guide was co-created with patients to help you get answers to the most important questions about starting a biologic treatment, establishing a treatment routine, what results you may expect, and understanding the available support services.

DOWNLOAD GUIDE
PAVBLU® Patient Brochure
PAVBLU™ Patient Brochure - Downloadable

Learn more about your retinal condition and how PAVBLU® may be able to help.
Get answers to important questions about starting a biologic treatment,
establishing a treatment routine and understanding the available support services.

DOWNLOAD Brochure (ENGLISH)
download brochure (spanish)

Important Safety Information

  • PAVBLU® (aflibercept-ayyh) Injection is a prescription medicine administered by injection into the eye. You should not use
    PAVBLU® if you have an infection in or around the eye, eye pain or redness, or known allergies to any of the ingredients in
    PAVBLU.
  • Injections into the eye with PAVBLU can result in an infection in the eye, retinal detachment (separation of retina from back of
    the eye) and, more rarely, serious inflammation of blood vessels in the retina that may include blockage. Call your doctor right
    away if you experience eye pain or redness, light sensitivity, or a change in vision after an injection.
  • In some patients, injections with PAVBLU may cause a temporary increase in eye pressure within 1 hour of the injection.
    Sustained increases in eye pressure have been reported with repeated injections, and your doctor may monitor this after each
    injection.
  • There is a potential but rare risk of serious and sometimes fatal side effects, related to blood clots, leading to heart attack or
    stroke in patients receiving PAVBLU.
  • The most common side effects reported in adult patients receiving aflibercept were increased redness in the eye, eye pain, cataract, vitreous (gel-like substance) detachment, vitreous floaters, moving spots in the field of vision, and increased pressure in the eye.
  • You may experience temporary visual changes after a PAVBLU injection and associated eye exams; do not drive or use
    machinery until your vision recovers sufficiently.
  • For additional safety information, please talk to your doctor and see the full Prescribing Information for PAVBLU.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

INDICATIONS

PAVBLU® (aflibercept-ayyh) is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular
Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic
Retinopathy (DR).

Please click here for full Prescribing Information for PAVBLU®.

Important Safety Information

  • PAVBLU® (aflibercept-ayyh) Injection is a prescription medicine administered by injection into the eye. You should not use PAVBLU® if you have an infection in or around the eye, eye pain or redness, or known allergies to any of the ingredients in PAVBLU.